DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Namenda (Memantine Hydrochloride) - Summary

 
 



NAMENDA SUMMARY

Namenda® (memantine hydrochloride) is an orally active NMDA receptor antagonist.

Namenda (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type.


See all Namenda indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Namenda (Memantine)

Medical News Today: Fat deposits in brain may hasten Alzheimer's disease
Source: Featured Health News from Medical News Today [2015.08.28]
New research suggests that abnormal fat deposits found in the brains of people who died from Alzheimer's disease could trigger or accelerate the condition.

Fat deposits in brain may hasten Alzheimer's disease
Source: Biology / Biochemistry News From Medical News Today [2015.08.28]
New research suggests that abnormal fat deposits found in the brains of people who died from Alzheimer's disease could trigger or accelerate the condition.

Waterford research on Alzheimer's disease suggests that measuring macular pigment offers potential as a biomarker of cognitive health
Source: Eye Health / Blindness News From Medical News Today [2015.08.25]
Results to be showcased internationally in the Journal of Alzheimer's DiseaseOngoing European Research Council-funded research at Waterford Institute of Technology's (WIT) Macular Pigment...

UNMC statewide study to test new model for caregivers of those with Alzheimer's disease, dementia
Source: Caregivers / Homecare News From Medical News Today [2015.08.20]
The responsibility of caring for loved ones with Alzheimer's disease or dementia can be overwhelming - physically, mentally and financially.

Alzheimer's Disease
Source: MedicineNet Advance Medical Directives Specialty [2015.08.13]
Title: Alzheimer's Disease
Category: Diseases and Conditions
Created: 8/26/2008 12:00:00 AM
Last Editorial Review: 8/13/2015 12:00:00 AM

more news >>

Published Studies Related to Namenda (Memantine)

Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response. [2014]
analysis of memantine... CONCLUSIONS: New definitions of clinical worsening based on MIDs represent a more

Genotype variant associated with add-on memantine in bipolar II disorder. [2014]
Memantine is a non-competitive N-methyl-d-asparate (NMDA) receptor antagonist with a mood-stabilizing effect. We investigated whether using valproic acid (VPA) plus add-on memantine to treat bipolar II disorder (BP-II) is more effective than using VPA alone (VPA + Pbo)...

Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. [2014]
and (iv) placebo in delaying clinical progression in AD... CONCLUSION: This large multicenter trial will address the unanswered question of

Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome (FXTAS): a double-blind brain potential study. [2014]
Older FMR1 premutation carriers may develop fragile X-associated tremor/ataxia syndrome (FXTAS), a neurodegenerative disorder manifesting cognitive deficits that often subsequently progress to dementia... Additional studies of memantine, perhaps in combination with other therapeutic agents, appear warranted, as symptomatic treatments and neuroprotective treatments are both needed for this recently recognized neurodegenerative disorder.

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2014]
rivastigmine, and memantine for the treatment of AD... CONCLUSIONS: Cholinesterase inhibitors and memantine are able to stabilize or

more studies >>

Clinical Trials Related to Namenda (Memantine)

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction? [Recruiting]
Many patients with epilepsy have memory deficits in the setting of otherwise normal intelligence. Unfortunately, the treatment options for memory dysfunction in patients with epilepsy are limited. The investigators are conducting a study to evaluate the effects of memantine for the treatment of verbal memory dysfunction in subjects with localization-related seizures. The study involves randomization to memantine therapy or placebo, with cognitive testing and EEG pre- and post-treatment, as well as after an open-label memantine treatment phase. The primary aim of this study is to evaluate the efficacy of memantine for the treatment of verbal memory dysfunction in subjects with left temporal lobe epilepsy. The investigators expect that verbal memory task performance will improve in those taking memantine, but not in those taking a placebo. The investigators propose that the expected benefit of memantine is specific to verbal memory in subjects with left temporal lobe seizures, rather than representing an overall improvement in cognitive function. The investigators expect no improvement on other cognitive tasks in either the memantine or placebo groups. The investigators will evaluate whether subjects with left temporal lobe epilepsy and memory difficulties have self-reported improvement in memory while taking memantine. The investigators expect improvement of self-rated memory function on the Quality of Life in Epilepsy Patient Inventory (QOLIE-89) in the memantine group, but no change on this scale in the placebo group.

Down Syndrome Memantine Follow-up Study [Recruiting]
The purpose of this research study is to learn if the medication Memantine Hydrochloride (the study medication) can help adolescents and young adults with Down syndrome. Dr. Alberto Costa and his research team want to see if a 16-week treatment with this medication can improve the participant's ability to learn and remember things. In this study, memantine hydrochloride will be used. Thus, the researchers want to learn whether the study drug can help improve memory in young adults with Down syndrome. To test the effect of the study medicine, half of the people in the study will receive the study medicine and half will receive a placebo (an inactive substance). Memantine is an approved medication to treat memory and thinking problems in persons with Alzheimer disease. However, little is known about the effect of this medication in persons with Down syndrome and it has not been approved for use in persons with Down syndrome.

The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems? [Not yet recruiting]
The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.

A Study of Memantine Hydrochloride (Namenda�) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders [Active, not recruiting]
The main objective of this study is to evaluate the safety and effectiveness of memantine (Namenda) for cognitive and behavioral impairment in adults ages 18-50 years with autism spectrum disorders (ASD). This is an exploratory, 12-week, pilot study, seeking to determine whether Namenda is efficacious and well tolerated in the treatment of adults with ASD. The study results will be used to generate hypotheses for a larger randomized controlled clinical trial with explicit hypotheses and sufficient statistical power.

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease [Completed]
The purpose of this study is to determine whether alpha-tocopherol, memantine (Namenda), or the combination will significantly delay clinical progression in mild to moderately demented patients with Alzheimer's disease compared to placebo.

more trials >>

Reports of Suspected Namenda (Memantine) Side Effects

Confusional State (7)Dizziness (5)Abnormal Behaviour (5)Tremor (5)Movement Disorder (4)Drug Interaction (4)OFF Label USE (4)Asthenia (4)Thinking Abnormal (3)Balance Disorder (3)more >>


Page last updated: 2015-08-28

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015